Pharming Group Profit Margin 2013-2021 | PHGUF
Current and historical gross margin, operating margin and net profit margin for Pharming Group (PHGUF) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Pharming Group net profit margin as of September 30, 2021 is 11.02%.
|Pharming Group Annual Profit Margins
|Pharming Group Quarterly Profit Margins
||Medical - Biomedical and Genetics
Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands.